Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up

Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long...

Descripción completa

Detalles Bibliográficos
Autores principales: McClure, Tess, Cui, Wanyuan, Asadi, Khashayar, John, Thomas, Testro, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867/
https://www.ncbi.nlm.nih.gov/pubmed/32912846
http://dx.doi.org/10.1136/bmjgast-2020-000487
_version_ 1783581060975558656
author McClure, Tess
Cui, Wanyuan
Asadi, Khashayar
John, Thomas
Testro, Adam
author_facet McClure, Tess
Cui, Wanyuan
Asadi, Khashayar
John, Thomas
Testro, Adam
author_sort McClure, Tess
collection PubMed
description Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.
format Online
Article
Text
id pubmed-7484867
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74848672020-09-18 Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up McClure, Tess Cui, Wanyuan Asadi, Khashayar John, Thomas Testro, Adam BMJ Open Gastroenterol Case Report Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy. BMJ Publishing Group 2020-09-10 /pmc/articles/PMC7484867/ /pubmed/32912846 http://dx.doi.org/10.1136/bmjgast-2020-000487 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Case Report
McClure, Tess
Cui, Wanyuan
Asadi, Khashayar
John, Thomas
Testro, Adam
Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
title Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
title_full Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
title_fullStr Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
title_full_unstemmed Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
title_short Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
title_sort case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867/
https://www.ncbi.nlm.nih.gov/pubmed/32912846
http://dx.doi.org/10.1136/bmjgast-2020-000487
work_keys_str_mv AT mccluretess caseofnivolumabinducedsclerosingcholangitislessonsfromlongtermfollowup
AT cuiwanyuan caseofnivolumabinducedsclerosingcholangitislessonsfromlongtermfollowup
AT asadikhashayar caseofnivolumabinducedsclerosingcholangitislessonsfromlongtermfollowup
AT johnthomas caseofnivolumabinducedsclerosingcholangitislessonsfromlongtermfollowup
AT testroadam caseofnivolumabinducedsclerosingcholangitislessonsfromlongtermfollowup

Ejemplares similares